Tamoxifen, which was approved by the FDA on December 30, 1977 has been has been used for over 40 years to treat hormone-receptor positive early and metastatic breast cancers. In the case of pt MB, as a clinician is it good to know that this option is available to offer to clients for adjuvant therapy for early-stage breast cancer: Research has shown that women who receive at least 5 years of adjuvant therapy with tamoxifen after having surgery for early-stage ER-positive breast cancer have reduced risks of breast cancer recurrence, including a new breast cancer in the other breast, and death at 15 years Treatment with tamoxifen lowers the risk of Breast cancer recurrence Breast cancer in the opposite breast. Death from breast cancer(2)Tamoxifen